← Back to Search

Monoclonal Antibodies

A Non-interventional Study to Assess the Influence of Automated Optical Coherence Tomography Image Enrichment With Segmentation Information on Disease Activity Assessment in Patients Treated With Licensed Anti- VEGF Injections (RAZORBILL Trial)

N/A
Waitlist Available
Research Sponsored by Novartis Pharmaceuticals
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up month 12
Awards & highlights
No Placebo-Only Group

Summary

RAZORBILL was an observational, multicenter, multinational, open-label, study designed primarily to investigate the influence of automated OCT image enrichment with segmentation information on disease activity assessment in nAMD patients treated with licensed anti-VEGFs

Eligible Conditions
  • Age-Related Macular Degeneration

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~month 12
This trial's timeline: 3 weeks for screening, Varies for treatment, and month 12 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Degree of agreement in classification of disease activity using enriched and non-enriched OCT images
Odds ratio of disease activity assessment from Optical Coherence Tomography (OCTs) with and without enrichment
Secondary study objectives
Acceptance of Discovery by physicians and whether it can optimize the ophthalmic clinical workflow
Best-corrected visual acuity change from baseline
Central Subfield Thickness (CST) change
+5 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Licensed anti-VEGFsExperimental Treatment3 Interventions
Patients being treated for nAMD with licensed anti-VEGFs
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
aflibercept
2015
Completed Phase 4
~2510
ranibizumab
2014
Completed Phase 4
~2190
brolucizumab
2021
Completed Phase 3
~750

Find a Location

Who is running the clinical trial?

Novartis PharmaceuticalsLead Sponsor
2,921 Previous Clinical Trials
4,253,818 Total Patients Enrolled
~102 spots leftby Jan 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top